Ignite Creation Date:
2025-12-24 @ 5:16 PM
Ignite Modification Date:
2025-12-27 @ 5:21 AM
Study NCT ID:
NCT04589650
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-17
First Post:
2020-10-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-19
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2031-01-17
Completion Date Type:
ESTIMATED
First Submit Date:
2020-10-14
First Submit QC Date:
None
Study First Post Date:
2020-10-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-12-23
Results First Submit QC Date:
None
Results First Post Date:
2025-02-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-02
Last Update Post Date:
2025-12-17
Last Update Post Date Type:
ESTIMATED